Evidence map›Paper›PMID 25992288›Full record

ArticleJournal for immunotherapy of cancer2015

Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer.

John B Liao, Kelsie J Ovenell, Erin E M Curtis, Denise L Cecil, Marlese R Koehnlein, Lauren R Rastetter, Ekram A Gad, Mary L Disis

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

John B LiaoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St., Seattle, WA 98195 USA ; Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican St., Seattle, WA 98109 USA.ORCID 0000-0002-3018-7879
Kelsie J OvenellDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St., Seattle, WA 98195 USA ; Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican St., Seattle, WA 98109 USA.
Erin E M CurtisDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St., Seattle, WA 98195 USA ; Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican St., Seattle, WA 98109 USA ; Swarthmore College, 500 College Ave, Swarthmore, PA 19081 USA.
Denise L CecilTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican St., Seattle, WA 98109 USA.
Marlese R KoehnleinTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican St., Seattle, WA 98109 USA.
Lauren R RastetterTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican St., Seattle, WA 98109 USA.
Ekram A GadTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican St., Seattle, WA 98109 USA.
Mary L DisisTumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican St., Seattle, WA 98109 USA.
University of Washington · USGynecologic Oncology Group · US

Funding

Vaccinating against IGFBP-2 to prevent ovarian cancer relapseP50CA083636 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DRESCHER, CHARLES, URBAN, NICOLE DENISE · 1999 to 2015
$35.1M
WOMEN'S REPRODUCTIVE HEALTH RESEARCH CAREER DEVELOPMENTK12HD001264 · NICHD · UNIVERSITY OF WASHINGTON · PI Barbara Ann Goff · 1998 to 2026
$8.6M
NCI NIH HHS P50 CA083636NICHD NIH HHS K12 HD001264
6 · The paper itself

Abstract

backgroundOvarian cancer is immunogenic and residual tumor volume after surgery is known to be prognostic. Ovarian cancer often follows a recurring-remitting course and microscopic disease states may present ideal opportunities for immune therapies. We sought to establish the immune profile of a murine model of ovarian cancer that allows in vivo tumor imaging and the quantitation of microscopic disease. RESULTS AND DISCUSSION: Baseline imaging and weight measurements were taken within 1 and 2 weeks after intraperitoneal tumor injection, respectively. Significantly higher photons per second from baseline imaging were first observed 5 weeks after tumor cell injection (p < 0.05) and continued to be significant through 8 weeks after injection (p < 0.01), whereas a significant increase in weight above baseline was not observed until day 56 (p < 0.0001). Expression of luc2 in ID8 cells did not alter the cellular immune microenvironment of the tumor. FOXP3+ T cells were more likely to be detected in the intraepithelial compartment and CD4+ T cells in the stroma as compared to CD3+ T cells, which were found equally in stroma and intraepithelial compartments.

conclusionsUse of an intraperitoneal tumor expressing a codon-optimized firefly luciferase in an immunocompetent mouse model allows tumor quantitation in vivo and detection of microscopic tumor burdens. Expression of this foreign protein does not significantly effect tumor engraftment or the immune microenvironment of the ID8 cells in vivo and may allow novel immunotherapies to be assessed in a murine model for their translational potential to ovarian cancers in remission or minimal disease after primary cytoreductive surgery or chemotherapy.

methodsMouse ovarian surface epithelial cells from C57BL6 mice transformed after serial passage in vitro were transduced with a lentiviral vector expressing a codon optimized firefly luciferase (luc2). Cell lines were selected and luc2 expression functionally confirmed in vitro. Cell lines were intraperitoneally (IP) implanted in albino C57BL/6/BrdCrHsd-Tyrc mice and albino B6(Cg)-Tyrc-2 J/J mice for serial imaging. D-luciferin substrate was injected IP and tumors were serially imaged in vivo using a Xenogen IVIS. Tumor take, weights, and luminescent intensities were measured. Immunohistochemistry was performed on tumors and assessed for immune infiltrates in stromal and intraepithelial compartments.

Indexed as

Immune therapiesMouse modelsOvarian cancer

Identifiers

PMID25992288
PMCPMC4437454
OpenAlexW1596163114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.